Lake Street analyst Mark Argento raised his price target for Health Insurance Innovations to $20 saying the company is continuing to see strong demand. The latest Affordable Care Act open enrollment period, which ended December 19, likely drove additional business to the company as "individuals got sticker shock and looked for cost effective insurance alternatives," Argento tells investors in a research note. He points out that Health Insurance Innovations raised its FY16 guidance four times over the year. The analyst keeps a Buy rating on the shares.